Analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to report earnings of ($0.34) per share for the current fiscal quarter, Zacks reports. Nine analysts have made estimates for Sarepta Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.52). Sarepta Therapeutics posted earnings per share of ($0.78) in the same quarter last year, which indicates a positive year over year growth rate of 56.4%. The company is scheduled to issue its next earnings report on Wednesday, October 24th.
According to Zacks, analysts expect that Sarepta Therapeutics will report full-year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($2.98) to ($1.28). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.40) per share, with EPS estimates ranging from ($2.77) to ($0.45). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.99). Sarepta Therapeutics had a negative return on equity of 19.34% and a negative net margin of 89.64%. The company had revenue of $73.53 million during the quarter, compared to the consensus estimate of $71.53 million. During the same quarter in the prior year, the firm earned ($0.48) earnings per share. The business’s revenue was up 110.0% compared to the same quarter last year.
In other news, CEO Douglas S. Ingram purchased 16,000 shares of the stock in a transaction on Wednesday, August 15th. The shares were acquired at an average price of $125.26 per share, with a total value of $2,004,160.00. Following the completion of the acquisition, the chief executive officer now directly owns 399,250 shares of the company’s stock, valued at $50,010,055. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.90% of the stock is owned by insiders.
Large investors have recently modified their holdings of the business. Kovack Advisors Inc. purchased a new position in Sarepta Therapeutics during the second quarter valued at approximately $217,000. Catalyst Capital Advisors LLC purchased a new position in Sarepta Therapeutics during the second quarter valued at approximately $2,445,000. State of Alaska Department of Revenue purchased a new position in Sarepta Therapeutics during the second quarter valued at approximately $993,000. World Asset Management Inc purchased a new position in Sarepta Therapeutics during the second quarter valued at approximately $287,000. Finally, Columbus Circle Investors purchased a new position in Sarepta Therapeutics during the second quarter valued at approximately $3,539,000. 89.99% of the stock is currently owned by institutional investors and hedge funds.
Shares of SRPT stock traded up $1.49 during trading hours on Wednesday, reaching $140.07. The company had a trading volume of 25,660 shares, compared to its average volume of 1,453,345. Sarepta Therapeutics has a one year low of $46.07 and a one year high of $176.50. The firm has a market capitalization of $10.73 billion, a PE ratio of -85.51 and a beta of 1.15. The company has a quick ratio of 9.89, a current ratio of 10.88 and a debt-to-equity ratio of 0.62.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Recommended Story: Asset Allocation and Your Retirement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.